ReviewJournal of neurology2014
Menopause in multiple sclerosis: therapeutic considerations.
Review in Journal of neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02710214 (Effect of a Tissue Selective Estrogen Complex on Menopausal Symptoms in Women With MS), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of a Tissue Selective Estrogen Complex on Menopausal Symptoms in Women With MS: A Pilot Trial.
Who cites it
14 citing papers in PubMed.
- Menopause and neurological disorders: a roadmap for research.Nature reviews. Neurology · 2026Review
- Expert Opinion on Age-Related Sex Hormone Changes and Hypogonadism in People With Multiple Sclerosis: A Delphi Consensus Program.Neurology. Clinical practice · 2026Review
- Multiple Sclerosis in Women: Impact of Different Life Stages on Treatment Decisions.CNS drugs · 2026Review
- Menopause and multiple sclerosis: A scoping review of symptoms, disease course, and lived experience.Maturitas · 2026Article
- The epidemiological trends of multiple sclerosis among women of child-bearing age: a global analysis from 1990 to 2021 and forecasts to 2040.Frontiers in immunology · 2026Article
- Article
- Sex differences in the neuronal transcriptome and synaptic mitochondrial function in the cerebral cortex of a multiple sclerosis model.Frontiers in neurology · 2023Article
- The X factor in neurodegeneration.The Journal of experimental medicine · 2022Article
- Sex Hormones as Key Modulators of the Immune Response in Multiple Sclerosis: A Review.Biomedicines · 2022Review
- Comprehensive Approach to Management of Multiple Sclerosis: Addressing Invisible Symptoms-A Narrative Review.Neurology and therapy · 2021Review
- Effects of Menopause in Women With Multiple Sclerosis: An Evidence-Based Review.Frontiers in neurology · 2021Review
- Autoimmune Disease in Women: Endocrine Transition and Risk Across the Lifespan.Frontiers in endocrinology · 2019Review
- Effects of multiple sclerosis and medications on menopausal age.The Journal of international medical research · 2018Article
- Motor Nerve Conduction Velocity In Postmenopausal Women with Peripheral Neuropathy.Journal of clinical and diagnostic research : JCDR · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While the onset of multiple sclerosis (MS) typically occurs during the childbearing years, many women living with MS are of perimenopausal age. There is frequent overlap between menopausal and MS-related symptoms and co-morbidities (e.g. sexual dysfunction, mood disorders and bladder function). Furthermore, some MS symptoms may be exacerbated by perimenopausal changes such as hot flashes or sleep disturbance. The MS neurologist may frequently be the first to become aware of these symptoms and to play a role in monitoring and managing them. In this review, we describe immunological and neurologic changes at menopause as they may impact MS. We then review common symptoms, including fatigue, depression, sexual function, pain and insomnia, and provide both behavioral and pharmacological suggestions for their management. Next, we discuss the need for osteoporosis and cancer screening in perimenopausal women with MS. Finally, we highlight important research gaps, including what effect, if any, the menopausal transition may play on MS disease course as well as the potential modulatory role of hormone replacement therapies.
Indexed as
Identifiers
24101131What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.